| Abstrakt: |
Researchers from Stanford University conducted a study on disease progression in patients with metabolic dysfunction-associated steatotic liver disease (MASLD) in the United States. The study compared outcomes in MASLD patients with and without liver biopsy, finding that patients who underwent biopsy had a higher risk of developing hepatocellular carcinoma, cirrhosis, and hepatic decompensation. The research suggests that biopsy patients may represent a selected group at higher risk for disease progression, particularly in clinical trials for MASLD therapies. The study was published in Digestive Diseases and can provide valuable insights for clinical patient management. [Extracted from the article] |
